GPC2 + B7-H3 bicistronic CAR T cells

GPC2 + B7-H3 bicistronic CAR T cells is an experimental cell-based immunotherapy designed to treat pediatric solid tumors, specifically neuroblastoma and medulloblastoma. This therapy utilizes a bicistronic "OR" chimeric antigen receptor (CAR) construct that simultaneously targets glypican 2 (GPC2) and CD276 (B7-H3). By targeting two antigens, the therapy aims to overcome tumor heterogeneity and antigen loss, which are common mechanisms of resistance in single-target CAR T therapies. Preclinical studies have demonstrated that these dual-targeting CAR T cells exhibit potent anti-tumor activity, enhanced persistence, and a less exhausted phenotype compared to single-target CARs. The development is led by researchers at institutions such as the Children's Hospital of Philadelphia, focusing on overcoming the interconvertible adrenergic and mesenchymal states in neuroblastoma where antigen expression can fluctuate.

Other names

GPC2.B7-H3 dual CAR T cellsGPC-2.B7-H3 dual CAR T cellsGPC 2.B7-H3 dual CAR T cellsGPC2/B7-H3 co-targeting bicistronic CAR T cellsGPC2-B7-H3 bicistronic CAR T cellsGPC-2-B7-H3 bicistronic CAR T cellsGPC 2-B7-H3 bicistronic CAR T cells